e-learning
resources
Stockholm 2007
Monday 17.09.2007
Pulmonary circulation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension
M. Zagolin, P. Uriarte, E. Wainstein, C. Parra (Santiago, Chile)
Source:
Annual Congress 2007 - Pulmonary circulation
Session:
Pulmonary circulation
Session type:
Thematic Poster Session
Number:
2099
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Zagolin, P. Uriarte, E. Wainstein, C. Parra (Santiago, Chile). Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension. Eur Respir J 2007; 30: Suppl. 51, 2099
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension
Year: 2009
Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension
Year: 2008
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Source: Eur Respir J 2006; 28: 1195-1203
Year: 2006
Hemodynamic testing of acute vasoreagibility to sildenafil in patients with severe pulmonary hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 705s
Year: 2004
Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 598s
Year: 2002
Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH)
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
Source: Eur Respir J 2011; 37: 70-77
Year: 2011
Sitaxsentan for pulmonary arterial hypertension (PAH) patients with clinical deterioration or significantly abnormal liver function test on bosentan
Source: Eur Respir J 2005; 26: Suppl. 49, 563s
Year: 2005
Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study
Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment
Year: 2007
Clinical and hemodynamic long term efficacy of sildenafil in primary pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005
Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Long-term effects of bosentan on the heart and pulmonary hemodynamics in pulmonary arterial hypertension, a comparison study with epoprostenol
Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy
Year: 2005
Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 205s
Year: 2005
Clinical characteristics, haemodynamics, and survival in patients with combined pulmonary fibrosis and emphysema and associated pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular medicine
Year: 2008
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy
Source: Eur Respir J 2005; 26: Suppl. 49, 476s
Year: 2005
Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension
Source: Eur Respir J 2015; 46: 405-413
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept